Clinical Trial

Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)

Study acronym: POWER1
Completed Phase 2/3
View on ClinicalTrials.gov →
Summary
A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults With Focal Seizures (POWER1)
Protocol Amendment History 5 changes
critical Trial completed 2026-08-11
notable Enrollment increased: 230 -> 255 participants 2026-08-11
notable Trial sites expanded: 26 -> 69 locations 2026-08-11
notable Primary completion pushed: 2025-11-24 -> 2026-05-14 2026-08-11
minor Completion pushed: 2025-12-08 -> 2026-05-14 2026-08-11
Trial Details
NCT Number NCT06999902
Lead Sponsor Praxis Precision Medicines
Conditions Focal Seizure
Enrollment 255 participants
Start Date 2024-12-11
Primary Completion 2026-05-14 (estimated)
Study Completion 2026-05-14 (estimated)
Updated on ClinicalTrials.gov 2026-08-10